by GlobeNewsWire | Sep 12, 2016 | Globe Newswire
MADISON, Wis., Sept. 12, 2016 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (Nasdaq:CLRB) (“the company”), an oncology-focused biotechnology company, today announces that its lead therapeutic compound, CLR 131, currently in a Phase 1 clinical trial for multiple...
by GlobeNewsWire | Aug 12, 2016 | Globe Newswire
MADISON, Wis., Aug. 12, 2016 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (Nasdaq:CLRB) (“the company”), an oncology-focused biotechnology company, today announces key accomplishments and its financial results for the second quarter of 2016, which ended June...
by GlobeNewsWire | Aug 11, 2016 | Globe Newswire
MADISON, Wis., Aug. 11, 2016 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (Nasdaq:CLRB) (“the company”), an oncology-focused biotechnology company, today announces key accomplishments and its financial results for the second quarter of 2016, which ended June...
by GlobeNewsWire | Aug 3, 2016 | Globe Newswire
MADISON, Wis., Aug. 03, 2016 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (Nasdaq:CLRB) (“the company”), an oncology-focused biotechnology company, today announced that it has received the second phase of a National Cancer Institute (“NCI”)...
by GlobeNewsWire | Jun 23, 2016 | Globe Newswire
MADISON, Wis., June 23, 2016 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (Nasdaq:CLRB) (“the company”), an oncology-focused biotechnology company, today announces the results of the first phase of a National Cancer Institute (NCI)-funded Small...